Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Altimmune (ALT – Research Report) today and set a price target of $18.00. The ...
Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $40.00.
Stifel Financial Corporation (Symbol: SF) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further ...
Investing.com -- Stifel downgraded Vertex (NASDAQ:VRTX), Inc to “Hold” from “Buy” and lowered its price target to $31 from $35, over the company’s investment strategy and valuation.
ST. LOUIS, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today reported selected operating results for January 31, 2025 in an effort to provide timely information to investors on ...
today announced that management will participate in Stifel’s 2025 Virtual CNS Forum. Vistagen’s President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Investing.com -- Stifel in a note dated Monday has raised its price target for Rheinmetall (ETR:RHMG), citing the potential for a surge in defense spending across NATO member states. The ...
Tuesday, Vulcan Materials Company (NYSE:VMC), currently trading at $239.77 with a market capitalization of $31.7 billion, received a positive assessment from Stifel analysts, as coverage was ...
Stifel Financial Corp. provides securities brokerage, investment banking, trading, investment advisory and related financial services. It operates through the following segments: Global Wealth ...
20 °C to -70 °C for 5 years in lyophilized state. SDS-PAGE analysis of GMP Human IL-3 Protein in both reducing (R) and non-reducing (NR) conditions. Coomassie Blue was used to stain the gel.
Quality Power IPO: Apply or not? Choice Broking adds a 'subscribe' tag to the book build issue: "At the upper price band, QPEEL is demanding an EV/S multiple of 5.9x, which is at a discount to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results